[{"address1": "711 Stewart Avenue", "address2": "Suite 200", "city": "Garden City", "state": "NY", "zip": "11530", "country": "United States", "phone": "215 345 0919", "website": "https://www.prophaselabs.com", "industry": "Diagnostics & Research", "industryKey": "diagnostics-research", "industryDisp": "Diagnostics & Research", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.", "fullTimeEmployees": 113, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ted William Karkus", "age": 64, "title": "Chairman & CEO", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 902200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jed A. Latkin", "age": 49, "title": "Chief Operating Officer & Head of Finance Department", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sergio  Miralles", "title": "Executive VP & Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamal  Obbad", "title": "Senior VP and Director of Sales & Marketing - Nebula Genomics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason  Karkus", "title": "President of Nebula Genomics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lance  Bisesar", "title": "Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.2599, "open": 0.26, "dayLow": 0.252, "dayHigh": 0.2753, "regularMarketPreviousClose": 0.2599, "regularMarketOpen": 0.26, "regularMarketDayLow": 0.252, "regularMarketDayHigh": 0.2753, "exDividendDate": 1653350400, "beta": -0.095, "forwardPE": -0.32575, "volume": 300759, "regularMarketVolume": 300759, "averageVolume": 609053, "averageVolume10days": 2119080, "averageDailyVolume10Day": 2119080, "marketCap": 7876947, "fiftyTwoWeekLow": 0.22, "fiftyTwoWeekHigh": 7.48, "priceToSalesTrailing12Months": 0.43828994, "fiftyDayAverage": 0.6076, "twoHundredDayAverage": 2.5608, "currency": "USD", "enterpriseValue": 39372608, "profitMargins": -1.46394, "floatShares": 15745319, "sharesOutstanding": 30226200, "sharesShort": 154056, "sharesShortPriorMonth": 231008, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0081, "heldPercentInsiders": 0.14337, "heldPercentInstitutions": 0.07635, "shortRatio": 7.04, "shortPercentOfFloat": 0.0097, "impliedSharesOutstanding": 30226200, "bookValue": 2.737, "priceToBook": 0.09521374, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -26310000, "trailingEps": -1.53, "forwardEps": 0.48, "lastSplitFactor": "2:1", "lastSplitDate": 853977600, "enterpriseToRevenue": 2.191, "enterpriseToEbitda": -1.457, "52WeekChange": -0.94990367, "SandP52WeekChange": 0.19995654, "lastDividendValue": 0.3, "lastDividendDate": 1653350400, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PRPH", "underlyingSymbol": "PRPH", "shortName": "ProPhase Labs, Inc.", "longName": "ProPhase Labs, Inc.", "firstTradeDateEpochUtc": 765466200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "072013b8-17d6-37c6-93e9-ffa6e6589859", "messageBoardId": "finmb_371755", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.2606, "targetHighPrice": 21.0, "targetLowPrice": 21.0, "targetMeanPrice": 21.0, "targetMedianPrice": 21.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 1781000, "totalCashPerShare": 0.093, "ebitda": -27014000, "totalDebt": 26818000, "quickRatio": 1.239, "currentRatio": 1.576, "totalRevenue": 17972000, "debtToEquity": 60.845, "revenuePerShare": 0.996, "returnOnAssets": -0.22975, "returnOnEquity": -0.50923, "grossProfits": -1638000, "freeCashflow": -3721250, "operatingCashflow": -14804000, "revenueGrowth": -0.813, "grossMargins": -0.09114, "ebitdaMargins": -1.50312, "operatingMargins": -3.1636999, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]